摘要
目的研究用脐血单个核细胞制备CD3AK细胞的抗肿瘤作用,探讨肿瘤生物治疗近期疗效的免疫指标及临床应用中的护理规范。方法分离脐血单个核细胞,用IL-2+CD3Ab诱导CD3AK细胞;测定肿瘤患者用CD3AK细胞治疗前后外周血单核细胞(PBMC)的自然杀伤(NK)活性,静脉滴注过程中严密观察患者体温和脉搏等反应。结果肿瘤患者输注CD3AK细胞一个疗程后,其PBMC的NK杀伤活性由63%升高到81%,平均升高28%,发热反应不到3%,大多在38℃以下,未经处理自行消退。结论(1)CD3AK细胞输注能明显提高肿瘤患者PBMC的NK活性;(2)CD3AK细胞输注安全有效,无明显副作用;(3)肿瘤患者PBMC的NK活性测定可望成为肿瘤生物治疗近期疗效的一个参数。
Objective To study the anti-tumor effect of CD3AK cell prepared from umbilical blood, to explore, the recent curative effect on tumor cases and seek better immune index for bio-therapy, and the nursing specification of CD3 AK cell in clinical application. Methods IL-2＋CD3 Ab was used to induce CD3AK cell frum umbilical blood mononuclear cells （UBMC）,the NK activity of peripheral blood mononuclear cells （PBMC） of 12 cases of malignant tumor patients were examined before and after CD3AK cell adopting immune therapy as well,The temperature and pulse were closely observed during the clinical application. Results The NK activity （killing K562 cell） of malignant tumor patient＇s PBMC had grown up to 81% from 63 % by CD3 AK cell transfusing, the even rising ratio is 28%, The fever cases is less than 3 %, major was under 38℃, and was returned to normal in 2 h without special treatment. Conchusion （1） The NK activity of malignant tumor patient＇s PBMC can be obviously elevated by transfusing CD3AK cell. （2） CD3AK cell transfusion is a safe and curative method in clinical application. （3） The test of NK activity of PBMC of malignant tumor patient may become a recent objective immune index for tumor bio-therapy.
出处
《中国实用护理杂志》
2005年第12期1-3,共3页
Chinese Journal of Practical Nursing
基金
广州市科技局重点科技攻关项目(编号:JB0299-Z-102-09)
